Literature DB >> 12664015

Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases.

Amel Mebazâa1, Hamouda Boussen, Rafiâa Nouira, Lilia Rokbani, Amel Ben Osman-Dhahri, Noureddine Bouaouina, Chedia Laouani-Kechrid, Bessem Louzir, Abdelmajid Zahaf, Mohamed Ridha Kamoun.   

Abstract

OBJECTIVE AND METHODS: The aim of our study was to report the epidemiologic, clinical, and biologic profiles of dermatomyositis (DM) associated with malignancy in patients from Tunisia. From January 1982 to January 2000, we collected retrospectively 20 case reports of DM associated with cancer from the different university hospital centers of Tunisia. Initial workup included anamnesis, clinical examination, cancer staging and classification, serum muscle enzymes (creatine phosphokinase, lactate dehydrogenase, aldolase, and transaminases), electromyography, and muscular biopsy. We calculated the median survival and mean value of all the variables. Comparisons of statistical tests were done with the Kruskal-Wallis test.
RESULTS: Among the 130 DM cases of our study, 20 were associated with cancer (15.38%). The mean age of our patients was 49.6 years and the sex ratio (female/male) was equal to 3. Cancers were mainly those of the breast (35%) and nasopharynx (25%). DM followed a paraneoplastic course in 90% of the cases. The profile of seric muscular enzymes showed a significant statistical difference (P =.05) between a group of patients with severe muscular weakness and a group with moderate muscle weakness only for creatine kinase. The median survival was 36.5 months after diagnosis of DM and 48.6 months after that of cancer. The 5-year actuarial survival was 38% as related to cancer and 16% as related to DM. Mortality was 45%, in 90% as a result of cancer.
CONCLUSIONS: In our study, nasopharyngeal carcinoma represents the second cancer associated with DM, after breast neoplasm, demonstrating the frequency of these 2 cancers in our country. Despite our reduced number of study samples, our study also suggests a relationship between severe muscle weakness and high seric muscle enzymes.

Entities:  

Mesh:

Year:  2003        PMID: 12664015     DOI: 10.1067/mjd.2003.208

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil.

Authors:  Luciena Cegatto Martins Ortigosa; Vitor Manuel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

2.  Nasopharyngeal carcinoma in dermatomyositis patients: A 10-year retrospective review in Hospital Selayang, Malaysia.

Authors:  J W Teoh; Razif M Yunus; Faridah Hassan; Norazmi Ghazali; Zainal A Z Abidin
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-15

Review 3.  Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.

Authors:  Eleni Tiniakou; Andrew L Mammen
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

4.  Malignancies in Korean patients with inflammatory myopathy.

Authors:  Sang-Won Lee; Sang Youn Jung; Min-Chan Park; Yong-Beom Park; Soo-Kon Lee
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

Review 5.  Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology.

Authors:  V Madan; H Chinoy; C E M Griffiths; R G Cooper
Journal:  Clin Exp Dermatol       Date:  2009-07       Impact factor: 3.470

6.  The spectrum of idiopathic inflammatory myopathies in South Africa.

Authors:  Keith J Chinniah; Girish M Mody
Journal:  Clin Rheumatol       Date:  2020-03-24       Impact factor: 2.980

7.  A Study on Dermatomyositis and the Relation to Malignancy.

Authors:  Andreea Daniela Tudorancea; Paulina Lucia Ciurea; Ananu Florentin Vreju; Adina Turcu-Stiolica; Cristina Elena Gofita; Cristina Criveanu; Anca Emanuela Musetescu; Stefan Cristian Dinescu
Journal:  Curr Health Sci J       Date:  2021-09-30

8.  Malignancy in dermatomyositis and polymyositis: analysis of 192 patients.

Authors:  Yao-Fan Fang; Yeong-Jian Jan Wu; Chang-Fu Kuo; Shue-Fen Luo; Kuang-Hui Yu
Journal:  Clin Rheumatol       Date:  2016-05-23       Impact factor: 3.650

9.  Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China.

Authors:  Ying Liu; Lulu Xu; Hongliang Wu; Na Zhao; Yanchun Tang; Xiaoping Li; Ying Liang
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

10.  Malignancy in dermatomyositis: A retrospective paired case-control study of 202 patients from Central China.

Authors:  Lili Chang; Lina Zhang; Haiquan Jia; Zhiyong Nie; Lei Zhang
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.